Literature DB >> 12477255

Gene therapy and biologic therapy with interleukin-4.

Hideho Okada1, Naruo Kuwashima.   

Abstract

For more than two decades, there has been a concerted effort to define the biology of, and develop the clinical applications for, cytokines that influence the immune system. However, intrinsic potency and toxicity have complicated application of cytokines as therapeutic agents when applied systemically. Indeed, one of the major characteristics of most cytokines is that they regulate immunity at a local or regional level, and systemic levels provided by most conventional schema fail to mimic the induction of an effective immune response. IL-4 has pleiotropic effects on immune cells of multiple lineages, endothelial cells and tumor cells. Accumulating data in pre-clinical studies demonstrate that sustained expression of IL-4 at the targeted organs or tissues may provide an effective means for therapy of variety of diseases including cancers and immunologic disorders. This review discusses biological properties and therapeutic applications of IL-4, particularly when it is delivered as a transgene in the settings of gene therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12477255     DOI: 10.2174/1566523023347625

Source DB:  PubMed          Journal:  Curr Gene Ther        ISSN: 1566-5232            Impact factor:   4.391


  7 in total

Review 1.  Cytokine networks in glioma.

Authors:  Kenichiro Iwami; Atsushi Natsume; Toshihiko Wakabayashi
Journal:  Neurosurg Rev       Date:  2011-06-09       Impact factor: 3.042

2.  Second-generation HIF-activated oncolytic adenoviruses with improved replication, oncolytic, and antitumor efficacy.

Authors:  T Cherry; S L Longo; Z Tovar-Spinoza; D E Post
Journal:  Gene Ther       Date:  2010-07-22       Impact factor: 5.250

3.  Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4.

Authors:  Dawn E Post; Eric M Sandberg; Michele M Kyle; Narra Sarojini Devi; Daniel J Brat; Zhiheng Xu; Mourad Tighiouart; Erwin G Van Meir
Journal:  Cancer Res       Date:  2007-07-15       Impact factor: 12.701

4.  Immunological response in mice bearing LM3 breast tumor undergoing pulchellin treatment.

Authors:  Djamile Cordeiro de Matos; Lívia Carolina Abreu de Ribeiro; Aline Tansini; Lucas Souza Ferreira; Marisa Campos Polesi Placeres; Lucas Luis Colombo; Iracilda Zeppone Carlos
Journal:  BMC Complement Altern Med       Date:  2012-07-24       Impact factor: 3.659

5.  Proinflammatory and Anti-Inflammatory Cytokines Mediated by NF-κB Factor as Prognostic Markers in Mammary Tumors.

Authors:  Gustavo Rodrigues Martins; Gabriela Bottaro Gelaleti; Marina Gobbe Moschetta; Larissa Bazela Maschio-Signorini; Debora Ap Pires de Campos Zuccari
Journal:  Mediators Inflamm       Date:  2016-02-16       Impact factor: 4.711

6.  Triterpenoid herbal saponins enhance beneficial bacteria, decrease sulfate-reducing bacteria, modulate inflammatory intestinal microenvironment and exert cancer preventive effects in ApcMin/+ mice.

Authors:  Lei Chen; Manreetpal S Brar; Frederick C C Leung; W L Wendy Hsiao
Journal:  Oncotarget       Date:  2016-05-24

7.  Cytokine Networks and Survivin Peptide-Specific Cellular Immune Responses Predict Improved Survival in Patients With Glioblastoma Multiforme.

Authors:  Liu Zhenjiang; Martin Rao; Xiaohua Luo; Davide Valentini; Anna von Landenberg; Qingda Meng; Georges Sinclair; Nina Hoffmann; Julia Karbach; Hans-Michael Altmannsberger; Elke Jäger; Inti Harvey Peredo; Ernest Dodoo; Markus Maeurer
Journal:  EBioMedicine       Date:  2018-06-29       Impact factor: 8.143

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.